# US 2026/0083856 A1 · Thiazolidine linkers for protein-drug conjugates and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083856 A1
- Document ID: US20260083856A1
- Status: Published application
- Kind: A1
- Application number: 19/325,974
- Filed: 2025-09-11
- Published: 2026-03-26
- Earliest claimed: 2024-09-20
- Assignees: R.P. Scherer Technologies, LLC
- Applicants: R.P. Scherer Technologies, LLC
- Inventors: Xiao Cai; Stepan Chuprakov; Reji Nair; Ayodele Ogunkoya; Matthew Smith
- Web page: https://patentgrep.com/patent/US20260083856A1

## CPC

- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/68037: {the drug being a camptothecin [CPT] or derivatives}
- A61K 47/6855: {the tumour determinant being from breast cancer cell}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- C07K 16/32: against translation products of oncogenes
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/40: characterized by post-translational modification
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure provides thiazolidine (Tz) linkers for protein-drug conjugates. In addition, the disclosure also encompasses compounds useful for producing such protein-drug conjugates, as well as methods for production of such protein-drug conjugates. The disclosure also encompasses methods of using the protein-drug conjugates for the treatment of a disease or disorder in a subject.

## Claims

### Claim 1

A conjugate of formula (I):
wherein:
R1 is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl;
R2 and R3 are each independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl;
LA is a first linker;
W1 is a drug; and
W2 is a peptide.

### Claim 2 (depends on 1)

The conjugate of claim 1, wherein R1 is hydrogen.

### Claim 3 (depends on 1)

The conjugate of claim 1, wherein R1 is alkyl.

### Claim 4 (depends on 1)

The conjugate of claim 1, wherein R2 and R3 are each hydrogen.

### Claim 5 (depends on 1)

The conjugate of claim 1, wherein one of R2 and R3 is hydrogen and one of R2 and R3 is alkyl.

### Claim 6 (depends on 1)

The conjugate of claim 1, wherein R2 and R3 are each alkyl.

### Claim 7 (depends on 1)

The conjugate of claim 1, wherein LA comprises:
wherein
a, b, c, d, e and f are each independently 0 or 1;
T1, T2, T3, T4, T5 and T6 are each independently selected from a covalent bond, (C1-C12)alkyl, substituted (C1-C12)alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, (EDA)w, (PEG)n, (AA)p, —(CR130H)m-, 4-amino-piperidine (4AP), an acetal group, a hydrazine, a disulfide, and an ester, wherein EDA is an ethylene diamine moiety, PEG is a polyethylene glycol, and AA is an amino acid residue or an amino acid analog, wherein each w is an integer from 1 to 20, each n is an integer from 1 to 30, each p is an integer from 1 to 20, and each m is an integer from 1 to 12;
V1, V2, V3, V4, V5 and V6 are each independently selected from the group consisting of a covalent bond, —CO—, —NR15—, —NR15(CH2)q—, —NR15(C6H4)—, —CONR15—, —NR15CO—, —C(O)O—, —OC(O)—, —O—, —S—, —S(O)—, —SO2—, —SO2NR15—, —NR15SO2— and —P(O)OH—, wherein each q is an integer from 1 to 6;
each R13 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, and substituted aryl; and
each R15 is independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, carboxyl, carboxyl ester, acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl.

### Claim 8 (depends on 7)

The conjugate of claim 7, wherein:
(PEG)n is
where n is an integer from 1 to 30;
EDA is an ethylene diamine moiety having the following structure:
where y is an integer from 1 to 6 and r is 0 or 1;
4-amino-piperidine (4AP) is
and
each R12 is independently selected from hydrogen, an alkyl, a substituted alkyl, a polyethylene glycol moiety, an aryl and a substituted aryl, wherein any two adjacent R12 groups may be cyclically linked to form a piperazinyl ring.

### Claim 9 (depends on 7)

The conjugate of claim 7, wherein one of T1, T2, T3, T4, T5, T6, V1, V2, V3, V4, V5 or V6 is a branched group.

### Claim 10 (depends on 9)

The conjugate of claim 9, wherein the branched group is selected from —CONR15— and 4AP.

### Claim 11 (depends on 9)

The conjugate of claim 9, wherein the branched group is attached to a compound of formula (II):
wherein:
LB is a second linker; and
W1a is a drug.

### Claim 12 (depends on 11)

The conjugate of claim 11, wherein LB comprises:
wherein
g, h, i, j, k and I are each independently 0 or 1;
T7, T8, T9, T10, T11 and T12 are each independently selected from a covalent bond, (C1-C12)alkyl, substituted (C1-C12)alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, (EDA)w, (PEG)n, (AA)p, —(CR130H)m-, 4-amino-piperidine (4AP), an acetal group, a hydrazine, a disulfide, and an ester, wherein EDA is an ethylene diamine moiety, PEG is a polyethylene glycol, and AA is an amino acid residue or an amino acid analog, wherein each w is an integer from 1 to 20, each n is an integer from 1 to 30, each p is an integer from 1 to 20, and each m is an integer from 1 to 12;
V7, V8, V9, V10, V11 and V12 are each independently selected from the group consisting of a covalent bond, —CO—, —NR15—, —NR15(CH2)q—, —NR15(C6H4)—, —CONR15—, —NR15CO—, —C(O)O—, —OC(O)—, —O—, —S—, —S(O)—, —SO2—, —SO2NR15—, —NR15SO2— and —P(O)OH—, wherein each q is an integer from 1 to 6;
each R13 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, and substituted aryl; and
each R15 is independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, carboxyl, carboxyl ester, acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl.

### Claim 13 (depends on 11)

The conjugate of claim 11, wherein W1 and W1a are the same drug.

### Claim 14 (depends on 11)

The conjugate of claim 11, wherein W1 and W1a are different drugs.

### Claim 15 (depends on 1)

The conjugate of claim 1, wherein the peptide comprises an antibody.

### Claim 16 (depends on 1)

The conjugate of claim 1, wherein the conjugate is selected from:

### Claim 17 (depends on 1)

A pharmaceutical composition comprising:
a conjugate of claim 1; and
a pharmaceutically acceptable excipient.

### Claim 18 (depends on 1)

A method comprising:
administering to a subject a conjugate of claim 1.

### Claim 19 (depends on 1)

A method of treating cancer in a subject, the method comprising:
administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a conjugate of claim 1, wherein the administering is effective to treat cancer in the subject.

### Claim 20 (depends on 1)

A method of producing a conjugate according to claim 1, the method comprising:
contacting an aldehyde-tagged peptide with a payload comprising a 1,2-aminothiol group under conditions to produce a conjugate of formula (I):
wherein:
R1 is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl;
R2 and R3 are each independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl;
LA is a first linker;
W1 is the payload; and
W2 is the peptide.
